Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?

Joy-Ann Tabanor, MBBS and Santhanam Lakshminarayanan, MBBS
Cleveland Clinic Journal of Medicine July 2019, 86 (7) 449-453; DOI: https://doi.org/10.3949/ccjm.86a.18084
Joy-Ann Tabanor
Fellow, Division of Rheumatology, University of Connecticut School of Medicine, Farmington, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Santhanam Lakshminarayanan
Chief, Division of Rheumatology, and Director, Rheumatology Fellowship Program, University of Connecticut School of Medicine, Farmington, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Pneumocystis jirovecii (previously carinii) pneumonia (PCP) is rare in patients taking biologic response modifiers for rheumatic disease.1–10 However, prophylaxis should be considered in patients who have granulomatosis with polyangiitis or underlying pulmonary disease, or who are concomitantly receiving glucocorticoids in high doses. There is some risk of adverse reactions to the prophylactic medicine.1,11–21 Until clear guidelines are available, the decision to initiate PCP prophylaxis and the choice of agent should be individualized.

THE BURDEN OF PCP

PCP is a life-threatening opportunistic infection. Common causes of immunosuppression are advanced human immunodeficiency virus (HIV) infection, hematologic malignancy, anti-rejection drugs, chemotherapy, glucocorticoid therapy, and other immunosuppressive drugs. Here, we focus on the risk of PCP with immunomodulatory biologic drugs used for rheumatic disease that deplete B cells or inhibit T-cell activation, cytokine production, or cytokine function (Table 1).22

View this table:
  • View inline
  • View popup
TABLE 1

Biologic agents used for rheumatic disease

In a meta-analysis23 of 867 patients who developed PCP and did not have HIV infection, 20.1% had autoimmune or chronic inflammatory disease and the rest were transplant recipients or had malignancies. The mortality rate was 30.6%.

PHARMACOLOGIC RISK FACTORS FOR PCP

Treatment with glucocorticoids

Treatment with glucocorticoids is an important risk factor for PCP, independent of biologic therapy.

Calero-Bernal et al11 reported on 128 patients with non-HIV PCP, of whom 114 (89%) had received a glucocorticoid for more than 4 weeks, and 98 (76%) were currently receiving one. The mean daily dose was equivalent to 27.73 mg of prednisone per day in those on glucocorticoids only, and 21.34 mg in those receiving glucocorticoids in combination with other immunosuppressants.

Park et al,12 in a retrospective study of Korean patients treated for rheumatic disease with high-dose glucocorticoids (≥ 30 mg/day of prednisone or equivalent for more than 4 weeks), reported an incidence rate of PCP of 2.37 per 100 patient-years in those not on prophylaxis.

Other studies13,14 have also found a prednisone dose greater than 15 to 20 mg per day for more than 4 weeks or concomitant use of 2 or more disease-modifying antirheumatic drugs to be a significant risk factor.13,14

Tumor necrosis factor alpha antagonists

A US Food and Drug Administration review1 of voluntary reports of adverse drug events estimated the incidence of PCP to be 2.3 per 100,000 patient-years with infliximab and 1.6 per 100,000 patient-years with etanercept. In most cases, other immunosuppressants were used concomitantly.1

Postmarketing surveillance2 of 5,000 patients with rheumatoid arthritis showed an incidence of suspected PCP of 0.4% within the first 6 months of starting infliximab therapy.

Komano et al,15 in a case-control study of patients with rheumatoid arthritis treated with infliximab, reported that all 21 patients with PCP were also on methotrexate (median dosage 8 mg per week) and prednisolone (median dosage 7.5 mg per day).

PCP has also been reported after adalimumab use in combination with prednisone, azathioprine, and methotrexate, as well as with certolizumab, golimumab, tocilizumab, abatacept, and rituximab.3–6,24–26

Rituximab

Calero-Bernal et al11 reported that 23% of patients with non-HIV PCP who were receiving immunosuppressant drugs were on rituximab.

Alexandre et al16 performed a retrospective review of 11 cases of PCP complicating rituximab therapy for autoimmune disease, in which 10 (91%) of the patients were also on corticosteroids, with a median dosage of 30 mg of prednisone daily. A literature review of an additional 18 cases revealed similar findings.

PATIENT RISK FACTORS FOR PCP

Certain clinical, laboratory, and pharmacologic factors are associated with increased risk of PCP (Table 2).3–6,9,17–19,21,22,27

View this table:
  • View inline
  • View popup
TABLE 2

Risk factors for Pneumocystis jirovecii pneumonia in patients on biologic therapy for rheumatic disease

Pulmonary disease, age, other factors

Komano et al,15 in their study of patients with rheumatoid arthritis treated with infliximab, found that 10 (48%) of 21 patients with PCP had preexisting pulmonary disease, compared with 11 (10.8%) of 102 patients without PCP (P < .001). Patients with PCP were older (mean age 64 vs 54, P < .001), were on higher median doses of prednisolone per day (7.5 vs 5 mg, P = .001), and had lower median serum immunoglobulin G (IgG) levels (944 vs 1,394 mg/dL, P < .001).15

Tadros et al13 performed a case-control study that also showed that patients with autoimmune disease who developed PCP had lower lymphocyte counts than controls on admission. Other risk factors included low CD4 counts and age older than 50.

Li et al17 found that patients with autoimmune or inflammatory disease with PCP were more likely to have low CD3, CD4, and CD8 cell counts, as well as albumin levels less than 28 g/L. They therefore suggested that lymphocyte subtyping may be a useful tool to guide PCP prophylaxis.

Granulomatosis with polyangiitis

Patients with granulomatosis with polyangiitis have a significantly higher incidence of PCP than patients with other connective tissue diseases.

Ward and Donald18 reviewed 223 cases of PCP in patients with connective tissue disease. The highest frequency (89 cases per 10,000 hospitalizations per year) was in patients with granulomatosis with polyangiitis, followed by 65 per 10,000 hospitalizations per year for patients with polyarteritis nodosa. The lowest frequency was in rheumatoid arthritis patients, at 2 per 10,000 hospitalizations per year. In decreasing order, diseases with significant associations with PCP were:

  • Polyarteritis nodosa (odds ratio [OR] 10.20, 95% confidence interval [CI] 5.69–18.29)

  • Granulomatosis with polyangiitis (OR 7.81, 95% CI 4.71–13.05)

  • Inflammatory myopathy (OR 4.44, 95% CI 2.67–7.38)

  • Systemic lupus erythematosus (OR 2.52, 95% CI 1.66–3.82).

Vallabhaneni and Chiller,26 in a meta-analysis including rheumatoid arthritis patients on biologics, did not find an increased risk of PCP (OR 1.77, 95% CI 0.42–7.47).

Park et al12 found that the highest incidences of PCP were in patients with granu-lomatosis with polyangiitis, microscopic polyangiitis, and systemic sclerosis. For systemic sclerosis, the main reason for giving high-dose glucocorticoids was interstitial lung disease.

Other studies19,20,28 also found an association with coexisting pulmonary disease in patients with rheumatoid arthritis.

CURRENT GUIDELINES

There are guidelines for primary and secondary prophylaxis of PCP in HIV-positive patients with CD4 counts less than 200/mm3 or a history of acquired immunodeficiency syndrome (AIDS)-defining illness.27 Additionally, patients with a CD4 cell percentage less than 14% should be considered for prophylaxis.27

Unfortunately, there are no guidelines for prophylaxis in patients taking immunosuppressants for rheumatic disease.

The recommended regimen for PCP prophylaxis in HIV-infected patients is trimethoprim-sulfamethoxazole, 1 double-strength or 1 single-strength tablet daily. Alternative regimens include 1 double-strength tablet 3 times per week, dapsone, aerosolized pentamidine, and atovaquone.27

There are also guidelines for prophylaxis in kidney transplant recipients, as well as for patients with hematologic malignancies and solid-organ malignancies, particularly those on chemotherapeutic agents and the T-cell-depleting agent alemtuzumab.29–31

Italian clinical practice guidelines for the use of tumor necrosis factor antagonists in inflammatory bowel disease recommend consideration of PCP prophylaxis in patients who are also on other immunosuppressants, particularly high-dose glucocorticoids.32

Prophylaxis has been shown to increase life expectancy and quality-adjusted life-years and to reduce cost for patients on immunosuppressive therapy for granulomatosis with polyangiitis.21 The European Society of Clinical Microbiology and Infectious Diseases recently produced consensus statements recommending PCP prophylaxis for patients on rituximab with other concomitant immunosuppressants such as the equivalent of prednisone 20 mg daily for more than 4 weeks.33 Prophylaxis was not recommended for other biologic therapies.34,35

THE RISKS OF PROPHYLAXIS

The risk of PCP should be weighed against the risk of prophylaxis in patients with rheumatic disease. Adverse reactions to sulfonamide antibiotics including disease flares have been reported in patients with systemic lupus erythematosus.36,37 Other studies have found no increased risk of flares in patients taking trimethoprim-sulfamethoxazole for PCP prophylaxis.12,38 A retrospective analysis of patients with vasculitis found no increased risk of combining methotrexate and trime-thoprim-sulfamethoxazole.39

KEY POINTS
  • PCP is an opportunistic infection with a high risk of death.

  • PCP has been reported with biologics used as immunomodulators in rheumatic disease.

  • PCP prophylaxis should be considered in patients at high risk of PCP, such as those who have granulomatosis with polyangiitis, underlying pulmonary disease or who are concomitantly taking glucocorticoids.

  • Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. US Food and Administration
    . Drug Safety update on TNF-alpha antagonists: infliximab and etanercept. https://wayback.archive-it.org/7993/20180127041103/ https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety_revision2.htm. Accessed May 3, 2019.
  2. ↵
    1. Takeuchi T,
    2. Tatsuki Y,
    3. Nogami Y,
    4. et al
    . Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67(2):189–194. doi:10.1136/ard.2007.072967
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Koike T,
    2. Harigai M,
    3. Ishiguro N,
    4. et al
    . Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012; 22(4):498–508. doi:10.1007/s10165-011-0541-5
    OpenUrlCrossRefPubMed
    1. Bykerk V,
    2. Cush J,
    3. Winthrop K,
    4. et al
    . Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015; 74(1):96–103. doi:10.1136/annrheumdis-2013-203660
    OpenUrlAbstract/FREE Full Text
    1. Koike T,
    2. Harigai M,
    3. Inokuma S,
    4. et al
    . Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011; 70(12):2148–2151. doi:10.1136/ard.2011.151092
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Harigai M,
    2. Ishiguro N,
    3. Inokuma S,
    4. et al
    . Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2016; 26(4):491–498. doi:10.3109/14397595.2015.1123211
    OpenUrlCrossRef
    1. Koike T,
    2. Harigai M,
    3. Inokuma S,
    4. et al
    . Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36(5):898–906. doi:10.3899/jrheum.080791
    OpenUrlAbstract/FREE Full Text
    1. Grubbs JA,
    2. Baddley JW
    . Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep 2014; 16(10):445. doi:10.1007/s11926-014-0445-4
    OpenUrlCrossRef
  5. ↵
    1. US Food and Administration
    . Drug FDA adverse event reporting system (FAERS) public dashboard. www.fda.gov/Drugs/Guidance-ComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed May 3, 2019.
  6. ↵
    1. Rutherford AI,
    2. Patarata E,
    3. Subesinghe S,
    4. Hyrich KL,
    5. Galloway JB
    . Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2018; 57(6):997–1001. doi:10.1093/rheumatology/key023
    OpenUrlCrossRefPubMed
  7. ↵
    1. Calero-Bernal ML,
    2. Martin-Garrido I,
    3. Donazar-Ezcurra M,
    4. Limper AH,
    5. Carmona EM
    . Intermittent courses of corticosteroids also present a risk for pneumonia in non-HIV patients. Can Respir J 2016; 2016:2464791. doi:10.1155/2016/2464791
    OpenUrlCrossRef
  8. ↵
    1. Park JW,
    2. Curtis JR,
    3. Moon J,
    4. Song YW,
    5. Kim S,
    6. Lee EB
    . Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77(5):644–649. doi:10.1136/annrheumdis-2017-211796
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Tadros S,
    2. Teichtahl AJ,
    3. Ciciriello S,
    4. Wicks IP
    . Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study. Semin Arthritis Rheum 2017; 46(6):804–809. doi:10.1016/j.semarthrit.2016.09.009
    OpenUrlCrossRefPubMed
  10. ↵
    1. Demoruelle MK,
    2. Kahr A,
    3. Verilhac K,
    4. Deane K,
    5. Fischer A,
    6. West S
    . Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken) 2013; 65(2):314–323. doi:10.1002/acr.21857
    OpenUrlCrossRef
  11. ↵
    1. Komano Y,
    2. Harigai M,
    3. Koike R,
    4. et al
    . Pneumocystis jiroveci pneumo nia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009; 61(3):305–312. doi:10.1002/art.24283
    OpenUrlCrossRefPubMed
  12. ↵
    1. Alexandre K,
    2. Ingen-Housz-Oro S,
    3. Versini M,
    4. Sailler L,
    5. Benhamou Y
    . Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11 cases and review of the literature. Eur J Intern Med 2018; 50:e23–e24. doi:10.1016/j.ejim.2017.11.014
    OpenUrlCrossRef
  13. ↵
    1. Li Y,
    2. Ghannoum M,
    3. Deng C,
    4. et al
    . Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis 2017; 57:108–115. doi:10.1016/j.ijid.2017.02.010
    OpenUrlCrossRef
  14. ↵
    1. Ward MM,
    2. Donald F
    . Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42(4):780–789. doi:10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M
    OpenUrlCrossRefPubMed
  15. ↵
    1. Katsuyama T,
    2. Saito K,
    3. Kubo S,
    4. Nawata M,
    5. Tanaka Y
    . Prophylaxis for pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther 2014; 16(1):R43. doi:10.1186/ar4472
    OpenUrlCrossRefPubMed
  16. ↵
    1. Tanaka M,
    2. Sakai R,
    3. Koike R,
    4. et al
    . Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 2012; 22(6):849–858. doi:10.1007/s10165-012-0615-z
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chung JB,
    2. Armstrong K,
    3. Schwartz JS,
    4. Albert D
    . Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43(8):1841–1848. doi:10.1002/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q
    OpenUrlCrossRefPubMed
  18. ↵
    1. Selmi C,
    2. Generali E,
    3. Massarotti M,
    4. Bianchi G,
    5. Scire CA
    . New treatments for inflammatory rheumatic disease. Immunol Res 2014; 60(2–3):277–288. doi:10.1007/s12026-014-8565-5
    OpenUrlCrossRefPubMed
  19. ↵
    1. Liu Y,
    2. Su L,
    3. Jiang SJ,
    4. Qu H
    . Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget 2017; 8(35):59729–59739. doi:10.18632/oncotarget.19927
    OpenUrlCrossRef
  20. ↵
    1. Desales AL,
    2. Mendez-Navarro J,
    3. Méndez-Tovar LJ,
    4. et al
    . Pneumocystosis in a patient with Crohn’s disease treated with combination therapy with adalimumab. J Crohns Colitis 2012; 6(4):483–487. doi:10.1016/j.crohns.2011.10.012
    OpenUrlCrossRefPubMed
    1. Kalyoncu U,
    2. Karadag O,
    3. Akdogan A,
    4. et al
    . Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007; 39(5):475–478. doi:10.1080/00365540601071867
    OpenUrlCrossRefPubMed
  21. ↵
    1. Vallabhaneni S,
    2. Chiller TM
    . Fungal infections and new biologic therapies. Curr Rheumatol Rep 2016; 18(5):29. doi:10.1007/s11926-016-0572-1
    OpenUrlCrossRefPubMed
  22. ↵
    1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents
    . Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed May 3, 2019.
  23. ↵
    1. Kourbeti IS,
    2. Ziakas PD,
    3. Mylonakis E
    . Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 2014; 58(12):1649–1657. doi:10.1093/cid/ciu185
    OpenUrlCrossRefPubMed
  24. ↵
    1. Bia M,
    2. Adey DB,
    3. Bloom RD,
    4. Chan L,
    5. Kulkarni S,
    6. Tomlanovich S
    . KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010; 56(2):189–218. doi:10.1053/j.ajkd.2010.04.010
    OpenUrlCrossRefPubMed
    1. Baden LR,
    2. Swaminathan S,
    3. Angarone M,
    4. et al
    . Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14:(7)882–913. pmid:27407129
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Cooley L,
    2. Dendle C,
    3. Wolf J,
    4. et al
    . Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44(12b):1350–1363. doi:10.1111/imj.12599
    OpenUrlCrossRefPubMed
  26. ↵
    1. Orlando A,
    2. Armuzzi A,
    3. Papi C,
    4. et al
    5. Italian Society of Gastroenterology
    6. Italian Group for the study of Inflammatory Bowel Disease
    . The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43(1):1–20. doi:10.1016/j.dld.2010.07.010
    OpenUrlCrossRefPubMed
  27. ↵
    1. Mikulska M,
    2. Lanini S,
    3. Gudiol C,
    4. et al
    . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24(suppl 2):S71–S82. doi:10.1016/j.cmi.2018.02.003
    OpenUrlCrossRefPubMed
  28. ↵
    1. Baddley J,
    2. Cantini F,
    3. Goletti D,
    4. et al
    . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect 2018; 24(suppl 2):S10–S20. doi:10.1016/j.cmi.2017.12.025
    OpenUrlCrossRefPubMed
  29. ↵
    1. Winthrop K,
    2. Mariette X,
    3. Silva J,
    4. et al
    . ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24(suppl 2):S21–S40. doi:10.1016/j.cmi.2018.02.002
    OpenUrlCrossRef
  30. ↵
    1. Petri M,
    2. Allbritton J
    . Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 1992; 19(2):265–269. pmid:1629825
    OpenUrlPubMed
  31. ↵
    1. Pope J,
    2. Jerome D,
    3. Fenlon D,
    4. Krizova A,
    5. Ouimet J
    . Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30(3):480–484. pmid:12610805
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Vananuvat P,
    2. Suwannalai P,
    3. Sungkanuparph S,
    4. Limsuwan T,
    5. Ngamjanyaporn P,
    6. Janwityanujit S
    . Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011; 41(3):497–502. doi:10.1016/j.semarthrit.2011.05.004
    OpenUrlCrossRefPubMed
  33. ↵
    1. Tamaki H,
    2. Butler R,
    3. Langford C
    . Abstract Number: 1755: Safety of methotrexate and low-dose trimethoprim-sulfamethoxazole in patients with ANCA-associated vasculitis. https://acrabstracts.org/abstract/safety-of-methotrexate-and-low-dose-trimethoprim-sulfa-methoxazole-in-patients-with-anca-associated-vasculitis/. Accessed May 3, 2019.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 86 (7)
Cleveland Clinic Journal of Medicine
Vol. 86, Issue 7
1 Jul 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Joy-Ann Tabanor, Santhanam Lakshminarayanan
Cleveland Clinic Journal of Medicine Jul 2019, 86 (7) 449-453; DOI: 10.3949/ccjm.86a.18084

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Joy-Ann Tabanor, Santhanam Lakshminarayanan
Cleveland Clinic Journal of Medicine Jul 2019, 86 (7) 449-453; DOI: 10.3949/ccjm.86a.18084
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • THE BURDEN OF PCP
    • PHARMACOLOGIC RISK FACTORS FOR PCP
    • PATIENT RISK FACTORS FOR PCP
    • CURRENT GUIDELINES
    • THE RISKS OF PROPHYLAXIS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis
  • Google Scholar

More in this TOC Section

  • Do I need to treat supine hypertension in my hospitalized patient?
  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Drug Therapy
  • Infectious Diseases
  • Preventive Care
  • Pulmonology
  • Rheumatology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire